Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

patent

If you want to know more about the patent, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the patent industry. More news about patent, are being released. Follow us / contact us for more patent information!
  • Drug Briefing: Olaparib

    2025-03-10

    Query Drug:OlaparibQuery Time:2025-03-10 13:13:19*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    2025-03-10

    This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025

    2025-02-24

    This week, there are 12 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - VIFOR PHARMA INC's VELTASSA, containing active ingredient PATIROMER SORBITEX CALCIUM - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 17 2025

    2025-02-17

    This week, there are 7 drugs in the patent and exclusivity list. They are: - DURYSTA by AbbVie Inc, containing active ingredient Bimatoprost - IXEMPRA KIT by R-Pharm US LLC, containing active ingredient Ixabepilone - XIFAXAN by Salix Pharmaceuticals Inc, containing active ingredient Rifaximin - DIFFERIN by Galderma Laboratories LP, containing active ingredient Adapalene - NEXLIZET by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid; Ezetimibe ​- NEXLETOL by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid - XARELTO by Janssen Pharmaceuticals Inc, containing active ingredient Rivaroxaban Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 10 2025

    2025-02-10

    This week, there are 6 drugs in the patent and exclusivity list. They are: - Tudorza Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide - Duaklir Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide and Formoterol Fumarate - Scenesse by Clinuvel Inc, containing active ingredient Afamelanotide - Hysingla ER by Purdue Pharma LP, containing active ingredient Hydrocodone Bitartrate - Izervay by Astellas Pharma US Inc, containing active ingredient Avacincaptad Pegol Sodium - Symdeko by Vertex Pharmaceuticals Inc, containing active ingredient Ivacaftor and Tezacaftor Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 03 2025

    2025-02-03

    This week, there are 4 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZOLINZA, containing active ingredient VORINOSTAT Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 27 2025

    2025-01-27

    This week, there are 10 drugs in the patent and exclusivity list. They are: - Myfembree by Sumitomo Pharma Switzerland, containing active ingredient Estradiol, Norethindrone Acetate, and Relugolix - Orgovyx by Sumitomo Pharma Switzerland, containing active ingredient Relugolix - Nulibry by Sentynl Therapeutics, containing active ingredient Fosdenopterin Hydrobromide - Delstrigo by Merck Sharp and Dohme, containing active ingredient Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate - Pifeltro by Merck Sharp and Dohme, containing active ingredient Doravirine - Geodon by Viatris Specialty, containing active ingredient Ziprasidone Hydrochloride - Reyvow by Eli Lilly, containing active ingredient Lasmiditan Succinate - Cabenuva Kit by ViiV Healthcare, containing active ingredient Cabotegravir and Rilpivirine - Vocabria by ViiV Healthcare, containing active ingredient Cabotegravir Sodium - Imbruvica by Pharmacyclics, containing active ingredient Ibrutinib Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 20 2025

    2025-01-20

    This week, there are 7 drugs in the patent and exclusivity list. They are: - CUMBERLAND PHARMACEUTICALS INC's SANCUSO, containing active ingredient GRANISETRON - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - EPIZYME INC's TAZVERIK, containing active ingredient TAZEMETOSTAT HYDROBROMIDE - EVOFEM INC's SOLOSEC, containing active ingredient SECNIDAZOLE - ADVANCED ACCELERATOR APPLICATIONS USA INC's LUTATHERA, containing active ingredient LUTETIUM LU 177 DOTATATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 13 2025

    2025-01-13

    This week, there are 6 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's BEPREVE, containing active ingredient BEPOTASTINE BESILATE - ITALFARMACO SPA's DUVYZAT, containing active ingredient GIVINOSTAT HYDROCHLORIDE - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO & ENTRESTO SPRINKLE, containing active ingredient SACUBITRIL; VALSARTAN - GLENMARK SPECIALTY SA's RYALTRIS, containing active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB Read More
  • Total 4 pages  Go to Page
  • Go